(American Society for Radiation Oncology) Head and neck cancers respond well to the anti-cancer drug erlotinib when it is administered before surgery and a stronger dose is given to patients who smoke, according to a study presented at the Multidisciplinary Head and Neck Cancer Symposium, sponsored by AHNS, ASCO, ASTRO and SNM.

Related Posts

The following two tabs change content below.
avatar

Editor

avatar

Latest posts by Editor (see all)